This site is intended for Healthcare Professionals only.

AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

Date:

Share post:

AstraZeneca said today (November 1) it will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for about £198 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.

The London-listed company also said that under the deal, which is expected to close in the fourth quarter of 2021, Covis will also cover certain ongoing development costs related to the medicines.

AstraZeneca, which has several new medicines in its pharmaceutical pipeline, including Covid-19 drugs and a vaccine, expects the agreement to help sharpen its focus on priority medicines in its respiratory and immunology portfolio.

Luxembourg-headquartered Covis had previously acquired the rights to other respiratory medicines Alvesco, Omnaris and Zetonna from AstraZeneca in 2018.

Eklira and Duaklir, used to treat chronic obstructive pulmonary disease (COPD) or smokers’ lung, had generated revenues of £105 million for AstraZeneca in geographies covered by a previous deal when the drugmaker had bought those rights.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

Pharmacists critical in helping people to practice self-care with confidence: survey

People are opting to visit pharmacists for self-care and are conscious of the positive impact it can have...

Sanofi Consumer Healthcare signs supply agreements with two wholesalers

Opella Healthcare, trading as Sanofi Consumer Healthcare, said it has entered into a dual partnership agreement with Alliance...

Sigma 2024 Conference: Rishi Sunak sends best wishes to all the participants

The 14th Annual Community Pharmacy Conference by Sigma Pharmaceuticals began on Monday, 25 February at Sun City, South...

Peak Pharmacy branches in Derbyshire and Staffordshire find new owners

‘There is a resurgence in demand for pharmacies that dispense below 4,000 items’ Independent pharmacy chain, Peak Pharmacy, has...